What is EU HTA and why should statisticians care?

As a statistician, have you ever wondered—why are statistical analyses for HTA dossiers differ from those in regulatory dossiers? Aren’t they both just benefit-risk assessments? In this podcast, we review some of the history and background of how HTA and regulatory decision making have common sources of information, but different utility functions for how they use that information. Why have we had a common European regulatory framework, but not a common HTA framework—until the near future. And what is the EU HTA Regulation? Why has it been established, what does it hope to accomplish…..and why does this matter to statisticians working in the pharmaceutical industry? This podcast is the first of a series of 4 exploring the role of statisticians and statistics in HTA analyses, and how the new European HTA Regulation that will first start being applied to medicinal products in 2025, will impact statisticians working with clinical (and non-clinical!) data to support and evaluate HTA decision making. Learn how you can get more involved in shaping the future of EU HTA as a statistician at the local and regional level.